in this issue
Regions :: Middle East
Lonza Signs Manufacturing Deal with Immune Pharmaceuticals
12:07 AM MDT | July 19, 2011 | Deepti Ramesh
Lonza says it has signed an exclusive contract for the production of Immune Pharmaceuticals’ (Tel Aviv, Israel) human immunoglobulin monoclonal antibody, Bertilimumab, under investigation for the potential treatment of several inflammatory disorders. Lonza will produce phase 2 clinical trial material at its mammalian development and manufacturing facility, under the terms of the deal. Immune is a biopharmaceutical company focused on the development of next generation monoclonal antibodies addressing unmet medical needs in the treatment of cancer and...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee